Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 4/20 | 0.56 |
| ▸ | TK2 | O00142 | 4/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12427212 | 1.00 | TLR4 (0.56) | TLR4TK2MGLLCNR1CNR2 | |
| SCHEMBL2201730 | 1.00 | TLR4 (0.56) | TLR4TK2MGLLCNR1CNR2 | |
| SCHEMBL2201728 | 1.00 | TLR4 (0.56) | TLR4TK2MGLLCNR1CNR2 | |
| SCHEMBL2201735 | 1.00 | TLR4 (0.56) | TLR4TK2MGLLCNR1CNR2 | |
| SCHEMBL2200160 | 0.96 | TLR4 (0.54) | TLR4TK2CNR2 | |
| SCHEMBL2200165 | 0.96 | TLR4 (0.54) | TLR4TK2CNR2 | |
| SCHEMBL2200169 | 0.96 | TLR4 (0.54) | TLR4TK2CNR2 | |
| SCHEMBL2309050 | 0.92 | TLR4 (0.55) | TLR4TK2MGLLCNR1CNR2 | |
| SCHEMBL2309057 | 0.92 | TLR4 (0.55) | TLR4TK2MGLLCNR1CNR2 | |
| SCHEMBL2309054 | 0.92 | TLR4 (0.55) | TLR4TK2MGLLCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729254-B2 | Derivative of glucose and vitamin F, compositions comprising it, uses and preparation process | L'OREAL (FR) | 2014-05-20 | — | — | US | disclosed |
| US-20090149396-A1 | DERIVATIVE OF GLUCOSE AND VITAMIN F, COMPOSITIONS COMPRISING IT, USES AND PREPARATION PROCESS | L'OREAL S.A. | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149396-A1 | DERIVATIVE OF GLUCOSE AND VITAMIN F, COMPOSITIONS COMPRISING IT, USES AND PREPARATION PROCESS | FASN, ELOVL6, FADS2 | TLR4 2700/4885TK2 980/4885MGLL 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.